SCHEMBL4398918

SCHEMBL4398918

CCOc1cc(O)c(F)c(N)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
POLB P06746 3/20 0.36
MAPK1 P28482 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
USP2 O75604 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CREBBP Q92793 1/20 0.34
TSHR P16473 3/20 0.33
GAA P10253 3/20 0.33
TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4403790 0.81 EP300 (0.43) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL4543726 0.80 KDM4E (0.44) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL4414696 0.79 ALDH1A1 (0.34) MAPTALDH1A1KDM4EMAPK1MEN1
SCHEMBL4404581 0.77 KDM4E (0.44) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL4407643 0.76 TSHR (0.40) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL4399086 0.76 KDM4E (0.40) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL4405901 0.74 MAPK1 (0.37) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL4395573 0.74 THRB (0.40) MAPTALDH1A1KDM4EPOLBMAPK1
SCHEMBL2882336 0.70 ALDH1A1 (0.41) MAPTALDH1A1MAPK1MEN1KMT2A
SCHEMBL4411834 0.70 EP300 (0.43) MAPTALDH1A1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 MAPT 3541/4885ALDH1A1 1779/4885KDM4E 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.